Tumor Response on CT Following Hypofractionated Stereotactic Ablative Body Radiotherapy for Small Hypervascular Hepatocellular Carcinoma With Cirrhosis
Authors:
- 1 December 2013
- journal article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 201 (6) , W812-W820
Abstract
The purpose of this study is to evaluate the CT appearances of tumor responses following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinomas (HCCs) and to assess the relationship between tumor responses and local control. Among 277 HCC tumors treated with stereotactic ablative body radiotherapy (35 or 40 Gy per five fractions), we selected enhanced lesions on arterial phase CT performed before stereotactic ablative body radiotherapy. Radiographic findings after stereotactic ablative body radiotherapy were evaluated during a 2-year follow-up period with the modified Response Evaluation Criteria in Solid Tumors. Local control and survival rates were calculated with the Kaplan-Meier method. Forty-two tumors with a median size of 2.1 cm (range, 1.0-3.8 cm) were selected with a median follow-up of 23.3 months (range, 9-56 months). Local recurrence was observed in two tumors after achieving a complete response (CR). The 2-year local control rate was 97%, and the overall survival rate was 81%. CR increased from 10 (24%) to 28 (67%) to 30 (71%) tumors at 3, 6, and 12 months after stereotactic ablative body radiotherapy. Overall CR at maximum follow-up was 39 tumors (93%), yet three enhanced tumors persisted for more than 2 years. The median time to achieve CR was 5.9 months (range, 1.2-34.2 months). The CR rate in hypervascular HCCs after hypofractionated stereotactic ablative body radiotherapy increased during the 2-year follow-up period. Cautious and continuous observation until tumor regrowth is considered relevant to evaluate a true effect of this treatment. Further studies for the optimal evaluation of treatment outcome after stereotactic ablative body radiotherapy are warranted.Keywords
This publication has 23 references indexed in Scilit:
- Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapyRadiation Oncology, 2012
- Stereotactic Body Radiation Therapy in Recurrent Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolizationCancer, 2012
- Stereotactic Body Radiotherapy for Primary Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological responseJournal of Surgical Oncology, 2011
- Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary ResultsTechnology in Cancer Research & Treatment, 2010
- Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancerBMC Cancer, 2010
- Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaJournal of Clinical Oncology, 2008
- Escalated Focal Liver Radiation and Concurrent Hepatic Artery Fluorodeoxyuridine for Unresectable Intrahepatic MalignanciesJournal of Clinical Oncology, 2000
- Rising Incidence of Hepatocellular Carcinoma in the United StatesNew England Journal of Medicine, 1999